Evidence map›Paper›PMID 41044511›Full record

SynthesisBMC pediatrics2025

A systematic review and meta-analysis of the treatment modalities available for children afflicted from cystic fibrosis.

Thamer Alshami Marghel Alruwaili, Muhannad Faleh Alanazi, Bashayer Farhan Alruwaili, Hamada K Fayed, Mahmoud Elsaeed, Talal Difallah Alnazi, Ahmad Aljared, Aasheq M W Alanazi, Abdulrahman M Alanazi, Saleh Dhifallah Alsharari and 2 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thamer Alshami Marghel AlruwailiDepartment of Pediatrics, College of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Muhannad Faleh AlanaziDepartment of Internal Medicine, Division of Radiology, College of Medicine, Jouf University, Sakaka, Saudi Arabia.
Bashayer Farhan AlruwailiDepartment of Family and Community Medicine, College of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Hamada K FayedDepartment of Chest Diseases, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Mahmoud ElsaeedDepartment of Chest Diseases, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Talal Difallah AlnaziCollege of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Ahmad AljaredCollege of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Aasheq M W AlanaziCollege of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Abdulrahman M AlanaziCollege of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Saleh Dhifallah AlsharariRiyadh Second cluster, MOH, Riyadh, Saudi Arabia.
Amirah AlshammariCollege of Medicine, Jouf University, Sakaka, 72388, Saudi Arabia.
Khaled SaadDepartment of Pediatrics, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt. ksaad8@yahoo.com.

Funding

Al Jouf University DGSSR-2023-01-02526
6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the efficacy of different treatment modalities in children with cystic fibrosis (CF) and determine the superiority of specific treatment modalities.

methodsA comprehensive literature search was conducted using different search strings across multiple databases, including PubMed, Cochrane Library, EMBASE, WOS, Scopus, CINAHL, PsycINFO, and Google Scholar, up to October 2024. Randomized controlled trials (RCTs), case-control studies and cohort studies were included.

resultsThe triple therapy indicated a significant reduction in CF-related complications, with an OR of 0.29 and an RR of 0.54, accompanied by low heterogeneity (I² = 0% for both). Physiotherapy and pulmonary exercises also yielded a beneficial effect, with an OR of 0.24 and an RR of 0.49, without heterogeneity. In contrast, nutritional interventions revealed non-significant outcomes (OR = 6.91 and RR = 2.63), suggesting the need to re-evaluate these strategies. Ivacaftor alone did not achieve statistical significance (OR = 0.34 and RR = 0.58), and the confidence intervals were broad, indicating uncertainty in the effect estimates. Azithromycin exhibited a positive effect on CF management, with an OR of 2.37 and an RR of 1.54. The overall pooled OR across all treatments was 0.71, with an RR not computed due to substantial heterogeneity (I²=93%).

conclusionThe study underscores the effectiveness of certain treatments, such as triple therapy and physiotherapy exercises, for CF while highlighting the considerable variability in treatment outcomes. Notably, nutritional interventions need to be carefully reassessed. The findings emphasize integrating physiotherapy and targeted pharmacological interventions into standard CF management tailored to individual needs.

Indexed as

Cystic FibrosisPhysical Therapy ModalitiesAnti-Bacterial AgentsAzithromycinChildCombined Modality TherapyExercise TherapyHumansAnti-Bacterial AgentsAzithromycinAzithromycinCystic fibrosisElexacaftorIvacaftorMeta-analysisPhysiotherapyTezacaftor

Identifiers

PMID41044511
PMCPMC12492919

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.